DOV Non-Opioid Bicifadine Starts Pivotal Trials In Chronic And Acute Pain
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
DOV Pharmaceutical has initiated two Phase III trials for its non-opioid analgesic bicifadine to support planned NDA filings in acute and chronic pain.